AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
暂无分享,去创建一个
D. Saur | A. Arlt | M. Schmidt-Supprian | M. Reichert | G. Schneider | M. Grade | M. Wirth | E. Hessmann | O. Krämer | R. Öllinger | Z. Hassan | C. Schneeweis | Sandra Diersch | K. Steiger | Lukas Krauß | Carolin Schneider | R. Rad | Daniele Lucarelli | C. Falcomatà | Zonera Hassan | Matthias Wirth
[1] D. Ennishi,et al. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma , 2022, iScience.
[2] R. Braren,et al. Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems , 2022, EMBO molecular medicine.
[3] Timothy E. Reddy,et al. Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity. , 2022, Developmental cell.
[4] N. Kraut,et al. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants , 2022, Cancer discovery.
[5] B. Kuster,et al. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment , 2021, Nature Cancer.
[6] David R. Jones,et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients , 2021, Cell.
[7] C. Der,et al. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. , 2022, Advances in cancer research.
[8] Joshua M. Dempster,et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects , 2021, Genome Biology.
[9] A. Trumpp,et al. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer , 2021, Nature Cancer.
[10] John G Doench,et al. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization , 2021, Cell reports.
[11] G. Schneider,et al. New insights into pancreatic cancer: notes from a virtual meeting. , 2021, Gastroenterology.
[12] S. Vicent,et al. The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF–MEK1/2–ERK1/2 Pathway , 2021, Cancer Research.
[13] D. Calvisi,et al. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. , 2021, Journal of hepatology.
[14] Wei Xie,et al. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer , 2020, Nature Cancer.
[15] S. C. Chafe,et al. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer , 2020, Cell reports. Medicine.
[16] R. Rad,et al. Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC , 2020, Molecular oncology.
[17] Laura E. Herring,et al. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers , 2020, Cell reports.
[18] P. Verde,et al. The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications’ door , 2020, Oncogene.
[19] Hans-Peter Lenhof,et al. GeneTrail 3: advanced high-throughput enrichment analysis , 2020, Nucleic Acids Res..
[20] A. Ashworth,et al. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer , 2020, Cell reports.
[21] Steven J. M. Jones,et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution , 2020, Nature Genetics.
[22] Kerstin B. Meyer,et al. BBKNN: fast batch alignment of single cell transcriptomes , 2019, Bioinform..
[23] Joshua M. Dempster,et al. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. , 2019, Cell reports.
[24] Alex Y. Ge,et al. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies , 2019, Science Signaling.
[25] Emanuel J. V. Gonçalves,et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens , 2019, Nature.
[26] E. Petricoin,et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer , 2019, Nature Medicine.
[27] E. Collisson,et al. Molecular subtypes of pancreatic cancer , 2019, Nature Reviews Gastroenterology & Hepatology.
[28] J. Yap,et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.
[29] Damian Szklarczyk,et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..
[30] D. Saur,et al. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis—A connection to licensing nodes , 2018, Small GTPases.
[31] Mazhar Adli,et al. CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response , 2018, Nature Communications.
[32] Leland McInnes,et al. UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..
[33] Channing J Der,et al. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.
[34] B. Neel,et al. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. , 2018, Cancer discovery.
[35] W. Birchmeier,et al. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase , 2018, Nature Medicine.
[36] S. Byers,et al. Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms , 2018, Clinical Cancer Research.
[37] James E. Bradner,et al. The dTAG system for immediate and target-specific protein degradation , 2018, Nature Chemical Biology.
[38] P. Zarrinkar,et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.
[39] Mathias J Friedrich,et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes , 2018, Nature.
[40] W. Weichert,et al. MTOR inhibitor-based combination therapies for pancreatic cancer , 2018, British Journal of Cancer.
[41] S. Reddy,et al. FOSL1 Promotes Kras‐induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation , 2017, American journal of respiratory cell and molecular biology.
[42] Fabian J Theis,et al. SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.
[43] Elizabeth H. Williams,et al. GRcalculator: an online tool for calculating and mining dose–response data , 2017, BMC Cancer.
[44] Beau R. Webber,et al. Rapid DNA replication origin licensing protects stem cell pluripotency , 2017, bioRxiv.
[45] S. Vicent,et al. All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS , 2017, Molecular & cellular oncology.
[46] P. Philip,et al. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial , 2017, JAMA oncology.
[47] Roland Rad,et al. Tissue-specific tumorigenesis: context matters , 2017, Nature Reviews Cancer.
[48] P. Khatri,et al. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer , 2017, Nature Communications.
[49] J. Wikel,et al. Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[50] R. Gibbs,et al. Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.
[51] Christoph Ziegenhain,et al. The impact of amplification on differential expression analyses by RNA-seq , 2016, Scientific Reports.
[52] R. Rad,et al. KrasG12D induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells , 2015, Oncogene.
[53] J. Wikel,et al. Identification of new chemical entities targeting APE1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) , 2016 .
[54] Evan Z. Macosko,et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.
[55] Fabian J Theis,et al. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling , 2015, Gut.
[56] Mallika Singh,et al. Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer , 2014, Molecular Cancer Therapeutics.
[57] M. Loda,et al. Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer , 2014, Clinical Cancer Research.
[58] Christian Veltkamp,et al. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer , 2014, Nature Medicine.
[59] D. Saur,et al. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib , 2014, Nucleic acids research.
[60] Joon-Oh Park,et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.
[61] R. Rad,et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. , 2013, Cancer cell.
[62] D. Saur,et al. Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models , 2013, Oncotarget.
[63] E. Moding,et al. Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice , 2011, Disease Models & Mechanisms.
[64] T. Ciuleanu,et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy , 2012, Investigational New Drugs.
[65] P. Yaswen,et al. A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells , 2009, PloS one.
[66] D. Saur,et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. , 2009, Gastroenterology.
[67] D. Saur,et al. Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. , 2007, The Journal of clinical investigation.
[68] P. Verde,et al. Fra‐1 promotes growth and survival in RAS‐transformed thyroid cells by controlling cyclin A transcription , 2007, The EMBO journal.
[69] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[70] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[71] E. Wagner,et al. The Fos‐related antigen Fra‐1 is an activator of bone matrix formation , 2004, The EMBO journal.
[72] E. Petricoin,et al. Erratum: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse (Cancer Cell (4) (437-450)) , 2004 .
[73] E. Petricoin,et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.
[74] Fen Wang,et al. Cancer cell culture—Methods and protocols , 2003, In Vitro Cellular & Developmental Biology - Animal.
[75] E. Wagner,et al. AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.